Trust After the Headlines: A CGT Communications Playbook for Uncertain Moments
American Society of Gene & Cell Therapy (ASGCT) Annual Meeting · Philadelphia, PA
Founder & CEO, Genoplex · Host, Rx for Biotech
Christopher
Leidli
The science has evolved.
The infrastructure hasn't.
The next decade won't be limited by scientific innovation. It will be limited by our ability to deliver those discoveries to patients.
20+ years across research, clinical development & commercial
- Amgen
- Johnson & Johnson
- Sanofi
- Bayer
- Array BioPharma
- Iovance
What I believe
We're investing billions in extraordinary therapies, then asking patients to navigate a system built decades before they existed.
We're entering an era where CAR-T and T cell therapies, gene therapies, radioligand therapies, bispecific antibodies, and precision medicines have the potential to transform or even cure diseases that were once considered untreatable.
That gap between the medicine and the system around it is the problem I've dedicated my career to solving.
After more than 20 years spanning research, clinical development, and commercial roles at leading biopharma companies including Amgen, Johnson & Johnson, Sanofi, Bayer, Array BioPharma, and Iovance, one observation has become impossible for me to ignore:
The biggest bottleneck in healthcare is no longer discovering breakthrough therapies. It's getting the right patient to the right specialist before time runs out.
Why I founded Genoplex
The missing infrastructure layer for advanced therapies.
- 01Identify patients earlier
- 02Orchestrate referrals
- 03Accelerate clinical trial recruitment
- 04Streamline treatment center workflows
- 05Improve access to some of the most advanced medicines ever created
Where I've worked
From research to improving patient access to care, 1992 to today.
- 1992Amgen
- Human Genome Sciences
- Johnson & Johnson
- Sanofi
- Bayer
- Array BioPharma
- Iovance Biotherapeutics
- Boulder Biotech Launch Specialists
- TodayGenoplexFounder & CEO
Education
- MBA, Healthcare PolicyUniversity of Southern California, Marshall School of Business
- MS, Molecular & Cellular BiophysicsUniversity of Cincinnati College of Medicine
Listen to the podcast
Rx for Biotech
Conversations with the leaders building the future of personalized medicines.
A healthcare education podcast helping patients, caregivers, and healthcare professionals understand the rapidly evolving world of advanced therapies, and how patients can access them. From cell and gene therapies to radiopharmaceuticals, immunotherapies, and next-generation treatments for cancer and autoimmune disease, it bridges the gap between breakthrough science and real-world patient care.
Powered by Therapy4me.ai
Featured conversations
- Nainesh Parikh, MDMoffitt Cancer CenterWatch on YouTube ↗
- Rodney GillespieNovartisWatch on YouTube ↗
- Navneet Majhail, MDSarah Cannon Research CenterWatch on YouTube ↗
- Christina Coughlin, MD, PhDAvactaWatch on YouTube ↗
- Jason TardioImmunic TherapeuticsWatch on YouTube ↗
- Jack Silberstein, PhDDeck BioWatch on YouTube ↗
- Bennett BordenClarion AIWatch on YouTube ↗
- Aron KnickerbockerAulos BiosciencesListen on SoundCloud ↗
- Chris Heery, MDArcellx / GileadListen on SoundCloud ↗
- Randy Teel, PhDArvinasListen on SoundCloud ↗
- Robb RichardsPenn MedicineListen on SoundCloud ↗
- James Zou, PhDStanfordListen on SoundCloud ↗
Public speaking & workshops
Keynotes on advanced therapies and AI in healthcare.
Christopher delivers a select number of keynotes and workshops at corporate events and sales meetings, helping leaders understand the power of advanced therapies and how AI is transforming life science companies and improving the patient experience.
Upcoming
Past engagements
The Impact of Generative AI on CGT: Best Practices and Real-World Applications for Communicators
ASGCT Annual Meeting
Session recordingAI in CGT: Previewing the Annual Meeting
With Dr. Rory Bricker-Anthony and Catherine Gillespie
Listen
Let's connect
Healthcare deserves infrastructure as innovative as the therapies themselves.
I'm always interested in connecting with leaders across clinical development, commercial strategy, market access, digital health, healthcare systems, and investment.
Because the future isn't simply discovering the next cure.
It's making sure every patient can reach it.